Design, Synthesis, and Biological Evaluation of Novel Selenium (Se-NSAID) Molecules as Anticancer Agents

Daniel Plano, Deepkamal N. Karelia, Manoj K. Pandey, Julian E. Spallholz, Shantu Amin, Arun K. Sharma

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The synthesis and anticancer evaluation of novel selenium-nonsteroidal anti-inflammatory drug (Se-NSAID) hybrid molecules are reported. The Se-aspirin analogue 8 was identified as the most effective agent in reducing the viability of different cancer cell lines, particularly colorectal cancer (CRC) cells, was more selective toward cancer cells than normal cells, and was >10 times more potent than 5-FU, the current therapy for CRC. Compound 8 inhibits CRC growth via the inhibition of the cell cycle in G1 and G2/M phases and reduces the cell cycle markers like cyclin E1 and B1 in a dose dependent manner; the inhibition of the cell cycle may be dependent on the ability of 8 to induce p21 expression. Furthermore, 8 induces apoptosis by activating caspase 3/7 and PARP cleavage, and its longer exposure causes increase in intracellular ROS levels in CRC cells. Taken together, 8 has the potential to be developed further as a chemotherapeutic agent for CRC.

Original languageEnglish (US)
Pages (from-to)1946-1959
Number of pages14
JournalJournal of Medicinal Chemistry
Volume59
Issue number5
DOIs
StatePublished - Mar 10 2016

Fingerprint

Selenium
Antineoplastic Agents
Colorectal Neoplasms
Anti-Inflammatory Agents
Cell Cycle
Pharmaceutical Preparations
Cyclin B1
Caspase 7
G2 Phase
Reducing Agents
Fluorouracil
Caspase 3
Cell Division
Aspirin
Neoplasms
Apoptosis
Cell Line
Growth
Therapeutics

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Drug Discovery

Cite this

Plano, Daniel ; Karelia, Deepkamal N. ; Pandey, Manoj K. ; Spallholz, Julian E. ; Amin, Shantu ; Sharma, Arun K. / Design, Synthesis, and Biological Evaluation of Novel Selenium (Se-NSAID) Molecules as Anticancer Agents. In: Journal of Medicinal Chemistry. 2016 ; Vol. 59, No. 5. pp. 1946-1959.
@article{fd9d42574cff4df4a4b744ecd8ce7275,
title = "Design, Synthesis, and Biological Evaluation of Novel Selenium (Se-NSAID) Molecules as Anticancer Agents",
abstract = "The synthesis and anticancer evaluation of novel selenium-nonsteroidal anti-inflammatory drug (Se-NSAID) hybrid molecules are reported. The Se-aspirin analogue 8 was identified as the most effective agent in reducing the viability of different cancer cell lines, particularly colorectal cancer (CRC) cells, was more selective toward cancer cells than normal cells, and was >10 times more potent than 5-FU, the current therapy for CRC. Compound 8 inhibits CRC growth via the inhibition of the cell cycle in G1 and G2/M phases and reduces the cell cycle markers like cyclin E1 and B1 in a dose dependent manner; the inhibition of the cell cycle may be dependent on the ability of 8 to induce p21 expression. Furthermore, 8 induces apoptosis by activating caspase 3/7 and PARP cleavage, and its longer exposure causes increase in intracellular ROS levels in CRC cells. Taken together, 8 has the potential to be developed further as a chemotherapeutic agent for CRC.",
author = "Daniel Plano and Karelia, {Deepkamal N.} and Pandey, {Manoj K.} and Spallholz, {Julian E.} and Shantu Amin and Sharma, {Arun K.}",
year = "2016",
month = "3",
day = "10",
doi = "10.1021/acs.jmedchem.5b01503",
language = "English (US)",
volume = "59",
pages = "1946--1959",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "5",

}

Design, Synthesis, and Biological Evaluation of Novel Selenium (Se-NSAID) Molecules as Anticancer Agents. / Plano, Daniel; Karelia, Deepkamal N.; Pandey, Manoj K.; Spallholz, Julian E.; Amin, Shantu; Sharma, Arun K.

In: Journal of Medicinal Chemistry, Vol. 59, No. 5, 10.03.2016, p. 1946-1959.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Design, Synthesis, and Biological Evaluation of Novel Selenium (Se-NSAID) Molecules as Anticancer Agents

AU - Plano, Daniel

AU - Karelia, Deepkamal N.

AU - Pandey, Manoj K.

AU - Spallholz, Julian E.

AU - Amin, Shantu

AU - Sharma, Arun K.

PY - 2016/3/10

Y1 - 2016/3/10

N2 - The synthesis and anticancer evaluation of novel selenium-nonsteroidal anti-inflammatory drug (Se-NSAID) hybrid molecules are reported. The Se-aspirin analogue 8 was identified as the most effective agent in reducing the viability of different cancer cell lines, particularly colorectal cancer (CRC) cells, was more selective toward cancer cells than normal cells, and was >10 times more potent than 5-FU, the current therapy for CRC. Compound 8 inhibits CRC growth via the inhibition of the cell cycle in G1 and G2/M phases and reduces the cell cycle markers like cyclin E1 and B1 in a dose dependent manner; the inhibition of the cell cycle may be dependent on the ability of 8 to induce p21 expression. Furthermore, 8 induces apoptosis by activating caspase 3/7 and PARP cleavage, and its longer exposure causes increase in intracellular ROS levels in CRC cells. Taken together, 8 has the potential to be developed further as a chemotherapeutic agent for CRC.

AB - The synthesis and anticancer evaluation of novel selenium-nonsteroidal anti-inflammatory drug (Se-NSAID) hybrid molecules are reported. The Se-aspirin analogue 8 was identified as the most effective agent in reducing the viability of different cancer cell lines, particularly colorectal cancer (CRC) cells, was more selective toward cancer cells than normal cells, and was >10 times more potent than 5-FU, the current therapy for CRC. Compound 8 inhibits CRC growth via the inhibition of the cell cycle in G1 and G2/M phases and reduces the cell cycle markers like cyclin E1 and B1 in a dose dependent manner; the inhibition of the cell cycle may be dependent on the ability of 8 to induce p21 expression. Furthermore, 8 induces apoptosis by activating caspase 3/7 and PARP cleavage, and its longer exposure causes increase in intracellular ROS levels in CRC cells. Taken together, 8 has the potential to be developed further as a chemotherapeutic agent for CRC.

UR - http://www.scopus.com/inward/record.url?scp=84960920207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960920207&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.5b01503

DO - 10.1021/acs.jmedchem.5b01503

M3 - Article

C2 - 26750401

AN - SCOPUS:84960920207

VL - 59

SP - 1946

EP - 1959

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 5

ER -